Table 1.

Study procedures and baseline and/or follow-up assessments

Visit number	Screening for eligibility	Randomization	Blood examination, urinary test, liver and renal function, ECG	Surgical indicators, surgical complications	Gynecological examination	Imaging test	SCCA/CA-125	Cervical liquid-based cytology	HPV test	Adverse events	EORTC QLQ-C30 v3.0; EORTC QLQ-CX24
V0	×
V1		×	×	×	×	×	×	×	×	×
V2 (3 months)					×	×	×	×		×	×
V3 (6 months)					×	×	×	×	×	×	×
V4 (9 months)					×	×	×	×		×	×
V5 (1 year)					×	×	×	×	×	×	×
V6 (15 months)					×	×	×	×		×	×
V7 (1.5 years)					×	×	×	×		×	×
V8 (21 months)					×	×	×	×		×	×
V9 (2 years)					×	×	×	×		×	×
V10 (2.5 years)					×	×	×	×	×	×	×
V11 (3 years)					×	×	×	×	×	×	×
V12 (3.5 years)					×	×	×	×	×	×	×
V13 (4 years)					×	×	×	×	×	×	×
V14 (4.5 years)					×	×	×	×	×	×	×
V15 (5 years)					×	×	×	×	×	×	×

ECG electrocardiogram, EORTC European Organization for Research and Treatment of Cancer, QLQ Quality of Life Questionnaire, SCCA SCC antigen test